Cat. No. 0898
Alternative Names: NIH 10443, C-CAM
Chemical Name: 14β-(p-Chlorocinnamoylamino)-7,8-dih
Biological ActivitySystemically active, irreversible μ-opioid receptor antagonist (apparent Ki values are 0.7, 1.9 and 5.7 nM for mouse μ, δ and κ receptors respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Broadbear et al (2000) Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, β-funaltrexamine, and β-chlornaltrexamine. J.Pharmacol.Exp.Ther. 294 933. PMID: 10945843.
Zernig et al (1996) Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioural assays. J.Pharmacol.Exp.Ther. 279 23. PMID: 8858971.
Burke et al (1994) Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J.Pharmacol.Exp.Ther. 271 715. PMID: 7965787.
Aceto et al (1989) Very long-acting narcotic antagonists. The 14β-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneimittelforschung 39 570. PMID: 2547389.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Clocinnamox mesylate from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Clocinnamox mesylate, supplier, irreversible, mu-opioids, m-opioids, μ-opioids, receptors, antagonists, Tocris Bioscience, μ Opioid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Fluorescent opioid antagonist; fluorescent-derivative of naloxone (Cat. No. 0599)BMS 986187
Potent δ-opioid receptor positive allosteric modulator
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands